Larimar Therapeutics, Inc. (NASDAQ:LRMR) is one of the Best Small-Cap Growth Stocks to Invest In Now. Recently, on June 19, Samantha Semenkow, an analyst from Citi, maintained a Buy rating on Larimar Therapeutics, Inc. (NASDAQ:LRMR), with a price target of $14.
The firm noted that the bullish sentiment is based on the company’s lead drug candidate, Nomlabofusp, which is being developed for Friedreich’s ataxia, a rare genetic disease. The analyst highlighted several upcoming catalysts, including new open-label clinical data and a planned rolling submission to the FDA by June 2026. (Larimar has now submitted the first module of its rolling BLA seeking accelerated approval for nomlabofusp).
The analyst believes that the drug can help achieve a carrier-like state, where symptoms become minimal or non-existent. Moreover, the firm also expects expanded data covering patients treated for a full year to show continued improvement on key functional measures, while maintaining good safety results.
Larimar Therapeutics, Inc. develops treatments for rare diseases using its cell-penetrating peptide technology platform.
READ NEXT: Top 10 Large-Cap Stocks to Invest In At 52-Week Lows and 12 High Growth Semiconductor Stocks to Buy Now.